Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 10/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1114596 | 1.00 | CCR2 (0.57) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL1114581 | 1.00 | CCR2 (0.57) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL1114535 | 1.00 | CCR2 (0.57) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL1114766 | 1.00 | CCR2 (0.57) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL31488325 | 0.77 | CCR2 (0.63) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL3743288 | 0.76 | CCR2 (0.61) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL14855848 | 0.76 | PSEN1 (0.50) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL15810270 | 0.76 | CCR2 (0.60) | CCR2CCR1CCR5CXCR4HTT | |
| SCHEMBL1114447 | 0.75 | PSEN1 (0.38) | CCR2CCR1CCR5CXCR4 | |
| SCHEMBL1114533 | 0.75 | PSEN1 (0.38) | CCR2CCR1CCR5CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | claimed |
| EP-1691814-B9 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2013-02-20 | — | — | EP | disclosed |
| EP-1691814-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| EP-2279741-A2 | Caprolactams and their use as anti-inflammatory agents | Cambridge Enterprise Ltd. (GB) | 2011-02-02 | — | — | EP | disclosed |
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2008-09-18 | — | — | US | disclosed |
| EP-1691814-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005053702-A2 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227724-A1 | 3-(alkanoyl or alkenoyl)amino-caprolactams; autoimmune diseases, asthma, osteoporosis, transplant rejection, psoriasis, Alzheimer's Disease, Multiple sclerosis, ALS; antitumor, antiarthritic, antifibrotic, and antiscarring agents | SMURF1, SMURF2, PSEN1 | CCR2 1075/4885CCR1 288/4885CCR5 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.